Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + IBI305 vs Sorafenib in First-Line Advanced HCC
NCT03794440Phase 3Unknown
- Sponsor
- Innovent Biologics
- Start
- Feb 2019
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sintilimab and IBI305 in hepatocellular carcinoma (HCC), sponsored by Innovent Biologics. Primary endpoints: Overall Survival up to 24 months and Progression-Free Survival up to 24 months. Status: unknown.
02
Drugs
sintilimabIBI305
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03794440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03794440.